Skip to content
OpenCapital
Get started

Nuvation Bio NUVB Debt Securities, Available-for-Sale, Unrealized Loss Position

Debt Securities, Available-for-Sale, Unrealized Loss Position at other companies

Tango Therapeutics logo
Tango TherapeuticsTNGX
——

Other financials

Income statement

See full
Revenue$83.2M+2,599%
Gross profit$9.8M+1,340%
Operating income$3.9M+107%
Net income$5.4M+110%
EPS (diluted)$0.01+106%

Balance sheet

See full
Cash & equivalents$125.4M+161%
Total debt$57.2M+401%
Total equity$319.6M-23.8%
Total assets$610.2M+23.9%

Cash flow

See full
Operating cash flow$5.1M+112%
CapEx$48.0K-33.3%
Free cash flow$5.0M+112%

Valuation

See full
Market cap$2.25B+150%

Profitability

See full
Gross margin54.3%+39.5pp
Operating margin-105%-52.0pp
Net margin-102.1%-50.6pp
FCF margin-93.5%-45.2pp

Returns & leverage

See full
Return on equity-39.5%-15.8pp
Debt / equity0.2×+0.2×
Current ratio7.4×-1.6×

Where this comes from

Reported directly by Nuvation Bio in its filing.

Tagged under the XBRL concept us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition.

The official record: Nuvation Bio’s 10-K, filed March 2, 2026, on SEC EDGAR. View the filing →

Ask your AI about Nuvation Bio's debt securities, available-for-sale, unrealized loss position.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Nuvation Bio's debt securities, available-for-sale, unrealized loss position?
Nuvation Bio (NUVB) reported debt securities, available-for-sale, unrealized loss position of $18.16M in Q4 2025.
How has Nuvation Bio's debt securities, available-for-sale, unrealized loss position changed year-over-year?
Nuvation Bio's debt securities, available-for-sale, unrealized loss position decreased by 90.3% year-over-year, from $186.93M to $18.16M.
What is the long-term trend for Nuvation Bio's debt securities, available-for-sale, unrealized loss position?
Over 4 years (2021 to 2025), Nuvation Bio's debt securities, available-for-sale, unrealized loss position has grown at a -56.8% compound annual growth rate (CAGR), from $523.28M to $18.16M.